This topic contains a solution. Click here to go to the answer

Author Question: IDEA requires that an eligibility reevaluation occur every five years, and it is required to be ... (Read 101 times)

nmorano1

  • Hero Member
  • *****
  • Posts: 598
IDEA requires that an eligibility reevaluation occur every five years, and it is required to be comprehensive.
 
  Indicate whether the statement is true or false

Question 2

Sensory problems should be considered prior to full assessment of a student.
 
  Indicate whether the statement is true or false



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

jsm54321

  • Sr. Member
  • ****
  • Posts: 328
Answer to Question 1

False
Explanation: IDEA requires reevaluations to be completed every three years. 2004 regulations indicate that such reevaluations do not need to be comprehensive.

Answer to Question 2

True
Explanation: Ruling out any sensory acuity problems is one of the first steps when assessing a student for special education programming. It is important to do so and refer to or consult with medical personnel if physical problems are suspected prior to embarking on a full psychoeducational evaluation.





 

Did you know?

Most fungi that pathogenically affect humans live in soil. If a person is not healthy, has an open wound, or is immunocompromised, a fungal infection can be very aggressive.

Did you know?

Nearly all drugs pass into human breast milk. How often a drug is taken influences the amount of drug that will pass into the milk. Medications taken 30 to 60 minutes before breastfeeding are likely to be at peak blood levels when the baby is nursing.

Did you know?

Atropine, along with scopolamine and hyoscyamine, is found in the Datura stramonium plant, which gives hallucinogenic effects and is also known as locoweed.

Did you know?

Women are 50% to 75% more likely than men to experience an adverse drug reaction.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library